| Title : The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells - Mashayekhi_2021_Prostaglandins.Other.Lipid.Mediat_158_106604 |
| Author(s) : Mashayekhi M , Wanjalla CN , Warren CM , Simmons JD , Ghoshal K , Pilkinton M , Bailin SS , Gabriel CL , Pozzi A , Koethe JR , Brown NJ , Kalams SA , Luther JM |
| Ref : Prostaglandins Other Lipid Mediat , 158 :106604 , 2021 |
| Abstract : Mashayekhi_2021_Prostaglandins.Other.Lipid.Mediat_158_106604 |
| ESTHER : Mashayekhi_2021_Prostaglandins.Other.Lipid.Mediat_158_106604 |
| PubMedSearch : Mashayekhi_2021_Prostaglandins.Other.Lipid.Mediat_158_106604 |
| PubMedID: 34922004 |
| Title : GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans - |
| Author(s) : Luther JM , Ray J , Wei D , Koethe JR , Hannah L , DeMatteo A , Manning R , Terker AS , Peng D , Nian H , Yu C , Mashayekhi M , Gamboa J , Brown NJ |
| Ref : Hypertension , 78 :1092 , 2021 |
| PubMedID: 34455816 |